CMPX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWCompass Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nov 9, 2026

8-K

Compass Therapeutics Receives FDA Regulatory Feedback on Tovecimig BLA Submission for Biliary Tract Cancer

Sep 22, 2026

8-K

Compass Therapeutics Reports Q2 2026 Financial Results and Pipeline Progress

Aug 6, 2026

8-K

Compass Therapeutics Presents Positive Phase 2/3 Data for Tovecimig in Biliary Tract Cancer

Jul 1, 2026

8-K

Compass Therapeutics, Inc. Adopts Second Amended and Restated Bylaws

Jun 22, 2026

8-K

Compass Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Aug 13, 2025

424B5

PENDING FIXED PRICE OFFERING

Aug 12, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 25,000,000

Jan 24, 2023

424B5

ATM | Offering amount: $75,000,000

Aug 1, 2022

424B5

SHELF OFFERING | Shares amount: 62,323,147 | Share price: $4.90

Dec 15, 2021

424B5

ATM | Offering amount: $75,000,000

Dec 15, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 12, 2026

S-3

December 2025 SHELF and ATM

Dec 30, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 27, 2025

S-3

SHELF | ATM | Offering amount: $300,000,000.00 EFFECTIVE

Aug 30, 2024

S-3

SHARE RESALE REGISTRATION | Shares amount: 25,000,000 | Share price: $4.11 EFFECTIVE

Dec 2, 2022

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Nov 1, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 28, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Lerner Neil (Reporting)

Oct 2, 2026

Lerner Neil (Reporting)

Sep 25, 2026

SCHEDULE 13G/A

Vivo Opportunity Fund Holdings, L.P. (Filed by)

Aug 14, 2026

SCHEDULE 13G

STATE STREET CORP (Filed by)

Aug 7, 2026

SCHEDULE 13G/A

BIOTECHNOLOGY VALUE FUND L P (Filed by)

May 15, 2026

4/A

Lerner Neil (Reporting)

Apr 30, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 8, 2026

CORRESP

Form CORRESP - Correspondence

Jan 5, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 2, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 9, 2024

CORRESP

Form CORRESP - Correspondence

Sep 4, 2024

LETTER

Form UPLOAD - SEC-generated letter

Sep 3, 2024

Compass Therapeutics, Inc. CMPX · SEC Filings